Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 78

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 4
Chunk 78
---
, intellectual property, commercial
arrangement, employment, and regulatory matters. While the outcome of these proceedings and claims cannot be predicted with certainty,
as of September 30, 2025, we were not party to any material legal or arbitration proceedings. No governmental proceedings are pending
or, to our knowledge, contemplated against us.

ITEM
1A. RISK FACTORS

Please
carefully consider the information set forth in this Quarterly Report on Form 10-Q, and the risk factors discussed in Part I, “Item
1A. Risk Factors” of our Annual Report on Form 10-K, which could materially affect our business, financial condition, or future
results. Any of the risk factors contained in our Annual Report on Form 10-K, as well as additional risks and uncertainties not presently
known to us or that we currently deem immaterial, could materially affect our business, results of operations, and financial condition
or future results, which in turn could materially and adversely affect the trading price of shares of our Common Stock. As of the date
of this Quarterly Report on Form 10-Q, there have been no material updates or changes with respect to the risk factors previously disclosed
in our Annual Report on Form 10-K, other than as set forth below, which should be read in conjunction with the risk described in our
Annual Report on Form 10-K.

Risks
Related to the STANDBY EQUITY PURCHASE AGREEMENT

Substantial
blocks of our common stock may be sold into the market as a result of the convertible notes we sold or will sell to YA II PN, Ltd. or
shares of Common Stock we may sell to YA II PN, Ltd., in each case, under the Standby Equity Purchase Agreement, if not terminated and
if and when available, which may cause the price of our Common Stock to decline.

On
October 27, 2025, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) and related Registration Rights
Agreement with YA II PN, Ltd. (“Yorkville”). Subject to the terms and conditions set forth therein, Yorkville agreed to
advance to us up to $6.0 million, in two tranches, less certain amounts (the “Pre-Paid Advances”) in exchange for
convertible promissory notes (each, a “Convertible Note” and, together, the “Convertible Notes”) issued by
us. On October 27, 2025, Yorkville disbursed